EDIT News and Press, Editas Medicine Inc. From 10/14/25

2025-10-14 18:18:10 ET Gene editing seems easy! It is exactly what it sounds like. Identify a part of the gene that isn’t right (i.e., mutated). Delete it. And go from there. Or perhaps you add something else to replace what you delete. It’s analogous to editing wr...

CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, potential best-in-class, one-time therapy to significantly reduce LDL-chole...

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) C...

2025-09-25 09:49:44 ET https://www.marketsheadlines.com/wp-content/uploads/2025/09/Healthcare-Innovation-Accelerates-as-Four-Converging-Forces-Drive-Early-Intervention-Focus.mp4 USA News Group News Commentary ...

Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus Canada NewsWire USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC , Sept. 25, 2025 /CNW/ -- America's...

2025-09-18 09:53:44 ET Editas Medicine, Inc. (NASDAQ: EDIT) is one of today’s top gainers. The company’s shares have moved 11.4% on the day to $3.03. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines ...

2025-09-02 11:32:42 ET Editas Medicine, Inc. (EDIT) Lead In Vivo Development Candidate Webinar (Transcript)... Read the full article on Seeking Alpha For further details see: Editas Medicine, Inc. (EDIT) Lead In Vivo Development Candidate Webinar (Transcript)

2025-09-02 11:14:24 ET Editas Medicine, Inc. - Special Call Company Participants Gilmore O’Neill - President, CEO & Director Linda Burkly - Executive VP & Chief Scientific Officer ... Read the full article on Seeking Alpha For further details...

2025-09-02 09:37:25 ET Toronto-based Satellos Bioscience (MSCL.TSX, MSCLF.OTCQB) is a clinical-stage small molecule development company focused on restoring natural muscle repair and regeneration for degenerative muscle diseases. Its proprietary discovery platform, MyoReGenX, identi...

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 ...